Multiple Myeloma Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Multiple Myeloma Information Center has current, evidence-based information for you. Get the facts about multiple myeloma early detection, treatment, and survivorship, and stay up to date with ongoing multiple myeloma research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Multiple Myeloma Community is the leading Social Media Application for Multiple Myeloma patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
Results from a clinical trial investigating a new T cell receptor (TCR) therapy that... Phase III Study Confirms Benefits of Lenalidomide Maintenance Therapy for Patients with Multiple Myeloma
Findings of Roswell Park-led research highlighted in poster discussion at ASCO 2015 Annual Meeting Study Demonstrates Superiority Of Kyprolis® over Velcade® in Patients With Relapsed Multiple Myeloma
Patients treated with Kyprolis lived twice as long than those treated with Velcade.
Sarah Holstein, MD, PhD from Roswell Park Cancer Institute recently answered your... Understanding Osteonecrosis of the Jaw
Cancer and its treatment can come with a variety of complications, some more serious... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse...
Multiple Myeloma Management
Moving On Aerobics helps women regain joy of movement and physical fitness after... Where Kids Can Be Kids… And Cancer Takes a Back Seat
Cancer camps for kids provide fun and camaraderie for children facing down a cancer... Pay it Forward
Survivors become peer mentors to newly diagnosed women and offer experience, insight,...
Multiple Myeloma Clinical Trials
06-108 – Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma (MM) Who Are Not Considered Candidates for High-Dose Chemotherapy (HDT) and Autologous Stem Cell Transplantation (SCT): VELCADE (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan, and Prednisone (VMP) (C05009)
C05009 – Randomized, Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myelome Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE? (Bortezomib) for Injection, Thalidomide, and Dexamethasone (VTD) versus VELCADE? (Bortezomib) and Dexamethasone (VD) versus VELCADE? (Bortezomib), Melphalan and Prednisone (VMP)
MM03 – PHASE II TRIAL OF ARSENIC TRIOXIDE AND THALIDOMIDE IN THE TREATMENT OF PATIENTS WITH REFRACTORY MULTIPLE MYELOMA